COMPANY:

Tempus

"Tempus AI, Inc...today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its RNA-based Tempus xR IVD device. xR IVD will be offered as a life sciences tool to support drug development programs."

"Tempus AI, Inc...today announced the publication of a study in JCO Precision Oncology validating the clinical utility of the company’s PurIST® algorithmic diagnostic. The study provides the largest real-world evidence to date supporting the integration of PurIST into routine clinical care for patients with advanced PDAC, with the aim of informing first-line chemotherapy selection and improving patient outcomes."

"Northwestern Medicine and Tempus AI, Inc...a notable expansion of their longstanding collaboration. Northwestern Medicine will be the first health system to integrate David, Tempus’ generative-AI clinical co-pilot, within its electronic health record (EHR) platform for its clinical care team. The expanded collaboration marks a new chapter in the organizations’ shared commitment to harnessing data and AI to advance patient care."

"Tempus AI, Inc...will participate in Morgan Stanley’s 23rd Annual Global Healthcare Conference. The conference will take place September 8-10 in New York City. Eric Lefkofsky, Founder and CEO of Tempus, and Jim Rogers, Chief Financial Officer, will participate in a fireside chat on September 8 from 1:05 to 1:40 p.m. EST."

"Tempus AI...today announced the acquisition of Paige, an AI company specializing in digital pathology. The acquisition allows Tempus to grow its dataset, expand its experienced technical team, and establish a strong footprint in digital pathology with an industry leading technology portfolio."

"These findings suggest that tumors with reduced checkpoint pathway activity may be less responsive to dual checkpoint inhibition, possibly reflecting an immune-cold microenvironment with limited T-cell infiltration and activation. Future prospective validation of these findings, including IHC, could inform precision medicine strategies for patients with advanced RCC."

"Personalis, Inc. (Nasdaq: PSNL) today announced an expansion and extension of its strategic collaboration with Tempus AI, Inc. (Nasdaq: TEM), adding a new indication, colorectal cancer (CRC), to the existing, exclusive commercialization agreement. The update means Personalis and Tempus will now work to bring to market the NeXT Personal® ultra-sensitive, tumor-informed minimal residual disease (MRD) test to detect cancer recurrence in four areas: breast, lung and colorectal cancers, and solid tumor immunotherapy monitoring. The addition of CRC follows the presentation of compelling interim analysis results from the VICTORI study at the 2025 American Association for Cancer Research (AACR) Annual Meeting, which demonstrated strong performance of NeXT Personal for detecting early signs of residual or recurrent CRC."

"Tempus AI...oday oday announced the expansion of its care pathway intelligence platform, Tempus Next, into breast cancer. Since its launch in 2024, Tempus Next has screened thousands of patients across its network of provider sites, helping close critical care gaps for patients with lung cancer. Now, the platform will support five different biomarker testing gaps specific to breast cancer with the goal of helping physicians deliver guideline-directed medical care to eligible patients."

"Ambry Genetics...announced today that a peer-reviewed study validating the accuracy of the Ambry CARE Program® (CARE) for hereditary cancer risk assessment has been published in the Journal of the National Comprehensive Cancer Network. The study, “Validation of a Digital Tool that Uses National Testing Guidelines to Identify Individuals at Risk for Hereditary Cancer,” demonstrated that the CARE program accurately interprets NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)1,2 with 99.5% accuracy, reinforcing its effectiveness as a digital risk assessment tool for identifying patients who may benefit from hereditary cancer-focused genetic testing and personalized care."

"Tempus AI, Inc...today announced xM for treatment response monitoring (TRM), a liquid biopsy assay intended to detect molecular response to immune-checkpoint inhibitor (ICI) therapy in advanced solid tumors. xM for TRM is the newest addition to Tempus’ growing portfolio of sensitive assays for monitoring molecular response and minimal residual disease (MRD)."

"Tempus AI,,,the adoption of AI to advance precision medicine and patient care, today announced that ten abstracts have been accepted for presentation at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting. The event will take place May 30 – June 3 in Chicago, Illinois. Tempus will present its cutting-edge clinical findings and innovative technologies, highlighting the company’s use of AI-driven solutions to advance precision oncology."

"Tempus AI...the adoption of AI to advance precision medicine and patient care, today announced the launch of its Fuses program. This initiative will harness Tempus’ proprietary dataset to generate valuable insights for both patient care and research, combining the power of its data and machine learning capabilities to develop an AI enabled-diagnostic platform offering physicians the largest suite of algorithmic tests designed to make precision medicine a reality."